The Board of Hofseth BioCare ASA has appointed Jon Olav Ødegård as new CEO of the company. Mr. Ødegård will assume the position by 1 April 2013. CEO Sjur Jenssen will continue in the company as Vice President for production, sales and distribution.
- Hofseth BioCare is growing and the construction of two new factories, as well as the further development of our international supply chain, demands increased management capacity. We are very pleased with the strengthening of our management team with Ødegårds qualifications and background, says Chairman of the Board Kjetil Olsen in Hofseth BioCare.
Jon Olav Ødegård comes from the position as manager of the area Factoring in the Sparebank 1 Group, where he was responsible for strategy and business development, compliance and risk management among other things. Further, Ødegård has worked as an adviser specialized in process and efficiency improvement in a number of industries.
As manager for production, sales and distribution, Sjur Jensen will get the opportunity to devote his time to pure operational processes and use his experiences from Pronova Biocare, where he was responsible for establishing the company's global supply chain.
- The management change came on my initiative and is according to what I find most suitable for the company, says Sjur Jenssen.
For further information please contact:
Kjetil Olsen, Chairman of the Board Hofseth BioCare ASA
Tel: +47 9061 4366
Email: kjetil.olsen@trols.no
About Hofseth BioCare:
Hofseth BioCare ASA is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. Hofseth BioCare's objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.